

CMOS DOCTOR INFORMATION SHEET



Australia's leading contract research organization focused exclusively
on medicinal cannabis treatments

What is the CMOS Study?

The Cannabinoid Medicine Observational Study (CMOS) is Australia's largest medicinal cannabis observational study. This study aims to collect important real-world evidence on Australian medicinal cannabis prescribing and its outcomes in a large patient cohort.

The CMOS study is an opportunity to contribute to the development of better treatment options using medicinal cannabinoids for various conditions.

Despite the growing demand for cannabinoid treatment options, there have been limited efforts to systematically collect data on prescribing patterns, patient outcomes and safety related to medicinal cannabis prescribing. As a result there is little supporting data around how prescribing has affected treatment outcomes.

The CMOS study aims to fill this gap and collect important real-world evidence on Australian medicinal cannabis prescribing and its outcomes. As Australia's largest medicinal cannabis observational study, CMOS aims to recruit 20,000 patients within a 5 year period which will create a dataset that is representative of the broader Australian community.

How do I register as a CMOS Doctor?

1. Register

Let us know you are interested by completing our online form at (link to CMOS website).

2. Confirmation

Look out for an email with further details & sign the CMOS study site agreement .

3. Training

Book a 30-minute training session with the CMOS study team.

CMOS Study Investigators:

- » Dr John Barlow - Principal Investigator
- » Niamh Moloney - Research Lead

What's involved?

Study training will be provided by the CMOS study team from Applied Cannabis Research.

Doctor will complete a 5 minute baseline enrolment form for eligible patients to enrol the patient onto the CMOS study.

There is minimal burden on the prescribing doctor. Patients will complete a consent form and online questionnaires throughout the 12 month period online via email. Surveys take from 2 to 10 minutes to complete and are completed monthly.

Participating doctors will be required to report adverse events to the CMOS study team on a quarterly basis.

The CMOS study team will report to each participating doctor with interim data also on a quarterly basis.

How will this benefit me and my patients?

Reimbursement (\$90) for each patient enrolled, with minimal work required from the doctor's end.

Access to medicinal cannabinoid research and prescribing support team.

Access to quarterly interim findings across the patient cohort on dosage, safety and potential efficacy.

Access to low cost study products.*

Improved patient outcomes (engagement in research has been generally shown to improve patient outcomes).

For more information & to register your interest

Please contact The CMOS study team on (+61)2 8294 6406 or email cmos@appliedcannabisresearch.com.au

*cmos study products may be subsidised by product companies